Search

Your search keyword '"O’Ferrall, Erin"' showing total 120 results

Search Constraints

Start Over You searched for: Author "O’Ferrall, Erin" Remove constraint Author: "O’Ferrall, Erin"
120 results on '"O’Ferrall, Erin"'

Search Results

1. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy

2. Myositis with prominent B cell aggregates may meet classification criteria for sporadic inclusion body myositis

4. Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report

5. A New Mutation in FIG4 Causes a Severe Form of CMT4J Involving TRPV4 in the Pathogenic Cascade

8. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

9. Motor Outcomes to Validate Evaluations in Facioscapulohumeral muscular dystrophy (MOVE FSHD): Preliminary Baseline Characteristics (S7.004)

10. Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis

12. Status and role of PABPN1 nuclear aggregates in Oculopharyngeal Muscular Dystrophy

13. Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion

14. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method

17. Response to Provincial Governments’ Decisions Regarding Monitoring for Adults with Spinal Muscular Atrophy

19. A National Spinal Muscular Atrophy Registry for Real-World Evidence

20. Autoantibody profiles delineate distinct subsets of scleromyositis.

23. Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy (S38.001)

25. The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities

28. BAG3P215L/KOMice as a Model of BAG3P209LMyofibrillar Myopathy

29. Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion

31. The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities.

34. Reply

42. Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood.

43. Inhibition of Aberrant and Constitutive Phosphorylation of the High-Molecular-Mass Neurofilament Subunit by CEP-1347 (KT7515), an Inhibitor of the Stress-Activated Protein Kinase Signaling Pathway.

44. MOESM4 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

45. MOESM1 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

46. MOESM2 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

47. MOESM2 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

48. MOESM5 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

49. MOESM4 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

50. MOESM5 of Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

Catalog

Books, media, physical & digital resources